These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28968759)

  • 21. HIVIS-DNA or HIVISopt-DNA priming followed by CMDR vaccinia-based boosts induce both humoral and cellular murine immune responses to HIV.
    Hinkula J; Petkov S; Ljungberg K; Hallengärd D; Bråve A; Isaguliants M; Falkeborn T; Sharma S; Liakina V; Robb M; Eller M; Moss B; Biberfeld G; Sandström E; Nilsson C; Markland K; Blomberg P; Wahren B
    Heliyon; 2017 Jun; 3(6):e00339. PubMed ID: 28721397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers.
    Mehendale S; Thakar M; Sahay S; Kumar M; Shete A; Sathyamurthi P; Verma A; Kurle S; Shrotri A; Gilmour J; Goyal R; Dally L; Sayeed E; Zachariah D; Ackland J; Kochhar S; Cox JH; Excler JL; Kumaraswami V; Paranjape R; Ramanathan VD
    PLoS One; 2013; 8(2):e55831. PubMed ID: 23418465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.
    Hayes P; Gilmour J; von Lieven A; Gill D; Clark L; Kopycinski J; Cheeseman H; Chung A; Alter G; Dally L; Zachariah D; Lombardo A; Ackland J; Sayeed E; Jackson A; Boffito M; Gazzard B; Fast PE; Cox JH; Laufer D
    Clin Vaccine Immunol; 2013 Mar; 20(3):397-408. PubMed ID: 23345581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).
    García F; Bernaldo de Quirós JC; Gómez CE; Perdiguero B; Nájera JL; Jiménez V; García-Arriaza J; Guardo AC; Pérez I; Díaz-Brito V; Conde MS; González N; Alvarez A; Alcamí J; Jiménez JL; Pich J; Arnaiz JA; Maleno MJ; León A; Muñoz-Fernández MA; Liljeström P; Weber J; Pantaleo G; Gatell JM; Plana M; Esteban M
    Vaccine; 2011 Oct; 29(46):8309-16. PubMed ID: 21907749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.
    O'Connell RJ; Excler JL; Polonis VR; Ratto-Kim S; Cox J; Jagodzinski LL; Liu M; Wieczorek L; McNeil JG; El-Habib R; Michael NL; Gilliam BL; Paris R; VanCott TC; Tomaras GD; Birx DL; Robb ML; Kim JH
    J Infect Dis; 2016 Jun; 213(12):1946-54. PubMed ID: 26908741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.
    Baden LR; Walsh SR; Seaman MS; Cohen YZ; Johnson JA; Licona JH; Filter RD; Kleinjan JA; Gothing JA; Jennings J; Peter L; Nkolola J; Abbink P; Borducchi EN; Kirilova M; Stephenson KE; Pegu P; Eller MA; Trinh HV; Rao M; Ake JA; Sarnecki M; Nijs S; Callewaert K; Schuitemaker H; Hendriks J; Pau MG; Tomaka F; Korber BT; Alter G; Dolin R; Earl PL; Moss B; Michael NL; Robb ML; Barouch DH;
    J Infect Dis; 2018 Jul; 218(4):633-644. PubMed ID: 29669026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.
    Walsh SR; Wilck MB; Dominguez DJ; Zablowsky E; Bajimaya S; Gagne LS; Verrill KA; Kleinjan JA; Patel A; Zhang Y; Hill H; Acharyya A; Fisher DC; Antin JH; Seaman MS; Dolin R; Baden LR
    J Infect Dis; 2013 Jun; 207(12):1888-97. PubMed ID: 23482644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.
    Greenberg RN; Hay CM; Stapleton JT; Marbury TC; Wagner E; Kreitmeir E; Röesch S; von Krempelhuber A; Young P; Nichols R; Meyer TP; Schmidt D; Weigl J; Virgin G; Arndtz-Wiedemann N; Chaplin P
    PLoS One; 2016; 11(6):e0157335. PubMed ID: 27327616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cellular and humoral responses to an HIV DNA prime by electroporation boosted with recombinant vesicular stomatitis virus expressing HIV subtype C Env in a randomized controlled clinical trial.
    Wilson GJ; Rodriguez B; Li SS; Allen M; Frank I; Rudnicki E; Trahey M; Kalams S; Hannaman D; Clarke DK; Xu R; Egan M; Eldridge J; Pensiero M; Latham T; Ferrari G; Montefiori DC; Tomaras GD; De Rosa SC; Jacobson JM; Miner MD; Elizaga M;
    Vaccine; 2023 Apr; 41(16):2696-2706. PubMed ID: 36935288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein.
    Hosseinipour MC; Innes C; Naidoo S; Mann P; Hutter J; Ramjee G; Sebe M; Maganga L; Herce ME; deCamp AC; Marshall K; Dintwe O; Andersen-Nissen E; Tomaras GD; Mkhize N; Morris L; Jensen R; Miner MD; Pantaleo G; Ding S; Van Der Meeren O; Barnett SW; McElrath MJ; Corey L; Kublin JG;
    Clin Infect Dis; 2021 Jan; 72(1):50-60. PubMed ID: 31900486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects.
    Hancock G; Morón-López S; Kopycinski J; Puertas MC; Giannoulatou E; Rose A; Salgado M; Hayton EJ; Crook A; Morgan C; Angus B; Chen F; Yang H; Martinez-Picado J; Hanke T; Dorrell L
    J Int AIDS Soc; 2017 May; 20(1):21171. PubMed ID: 28537062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.
    Mothe B; Climent N; Plana M; Rosàs M; Jiménez JL; Muñoz-Fernández MÁ; Puertas MC; Carrillo J; Gonzalez N; León A; Pich J; Arnaiz JA; Gatell JM; Clotet B; Blanco J; Alcamí J; Martinez-Picado J; Alvarez-Fernández C; Sánchez-Palomino S; Guardo AC; Peña J; Benito JM; Rallón N; Gómez CE; Perdiguero B; García-Arriaza J; Esteban M; López Bernaldo de Quirós JC; Brander C; García F;
    J Antimicrob Chemother; 2015; 70(6):1833-42. PubMed ID: 25724985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.
    Guardo AC; Gómez CE; Díaz-Brito V; Pich J; Arnaiz JA; Perdiguero B; García-Arriaza J; González N; Sorzano COS; Jiménez L; Jiménez JL; Muñoz-Fernández MÁ; Gatell JM; Alcamí J; Esteban M; López Bernaldo de Quirós JC; García F; Plana M;
    PLoS One; 2017; 12(10):e0186602. PubMed ID: 29065142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individuals.
    Morrow MP; Tebas P; Yan J; Ramirez L; Slager A; Kraynyak K; Diehl M; Shah D; Khan A; Lee J; Boyer J; Kim JJ; Sardesai NY; Weiner DB; Bagarazzi ML
    Mol Ther; 2015 Mar; 23(3):591-601. PubMed ID: 25531694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.
    Kalams SA; Parker SD; Elizaga M; Metch B; Edupuganti S; Hural J; De Rosa S; Carter DK; Rybczyk K; Frank I; Fuchs J; Koblin B; Kim DH; Joseph P; Keefer MC; Baden LR; Eldridge J; Boyer J; Sherwat A; Cardinali M; Allen M; Pensiero M; Butler C; Khan AS; Yan J; Sardesai NY; Kublin JG; Weiner DB;
    J Infect Dis; 2013 Sep; 208(5):818-29. PubMed ID: 23840043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
    Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
    Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Safety and Immunogenicity of GTU
    Haidari G; Day S; Wood M; Ridgers H; Cope AV; Fleck S; Yan C; Reijonen K; Hannaman D; Spentzou A; Hayes P; Vogt A; Combadiere B; Cook A; McCormack S; Shattock RJ
    Front Immunol; 2019; 10():2911. PubMed ID: 31921170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo electroporation in DNA-VLP prime-boost preferentially enhances HIV-1 envelope-specific IgG2a, neutralizing antibody and CD8 T cell responses.
    Huang X; Zhu Q; Huang X; Yang L; Song Y; Zhu P; Zhou P
    Vaccine; 2017 Apr; 35(16):2042-2051. PubMed ID: 28318765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults.
    Mulligan MJ; Russell ND; Celum C; Kahn J; Noonan E; Montefiori DC; Ferrari G; Weinhold KJ; Smith JM; Amara RR; Robinson HL;
    AIDS Res Hum Retroviruses; 2006 Jul; 22(7):678-83. PubMed ID: 16831092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial.
    Baden LR; Karita E; Mutua G; Bekker LG; Gray G; Page-Shipp L; Walsh SR; Nyombayire J; Anzala O; Roux S; Laher F; Innes C; Seaman MS; Cohen YZ; Peter L; Frahm N; McElrath MJ; Hayes P; Swann E; Grunenberg N; Grazia-Pau M; Weijtens M; Sadoff J; Dally L; Lombardo A; Gilmour J; Cox J; Dolin R; Fast P; Barouch DH; Laufer DS;
    Ann Intern Med; 2016 Mar; 164(5):313-22. PubMed ID: 26833336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.